Kyverna Therapeutics, Inc.
KYTX · XNASCIK 1994702fmd_1GG1W0P95HSQFK6T03M9YN0FX1Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 50 | 112 | 134 |
| Total operating expenses | 62 | 143 | 170 |
| Operating income | (62) | (143) | (170) |
| Interest expense | 0 | 0 | 0 |
| Interest and investment income | 2 | 15 | 9 |
| Other non-operating income (expense) | 2 | 15 | 9 |
| Income tax expense | 0 | 0 | 0 |
| Net income | (60) | (127) | (161) |